What liver tests should I order to assess for metabolic-associated fatty liver disease (MAFLD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What Liver Tests to Order for metALD Assessment

Order AST, ALT, and platelet count as your initial blood tests, then calculate FIB-4 to stratify fibrosis risk 1. These basic tests allow immediate risk stratification and determine whether additional testing is needed.

Initial Blood Work

The foundation of metALD (MASLD) assessment requires three essential laboratory values 1:

  • AST (aspartate aminotransferase)
  • ALT (alanine aminotransferase)
  • Platelet count

These three values enable automatic calculation of FIB-4, the recommended first-line non-invasive fibrosis test. Guidelines strongly recommend that FIB-4 be automatically calculated and systematically reported when liver tests are ordered in at-risk populations 1.

Risk Stratification Using FIB-4

After obtaining basic labs, interpret FIB-4 using age-adjusted thresholds 2:

For patients <65 years old:

  • **FIB-4 <1.3**: Low risk—rules out advanced fibrosis with high negative predictive value (>90%)
  • FIB-4 1.3-2.67: Indeterminate—proceed to second-tier testing
  • FIB-4 >2.67: High risk—proceed to second-tier testing

For patients ≥65 years old:

  • FIB-4 <2.0: Low risk threshold (higher cut-off needed due to age effect on score)
  • FIB-4 >2.0: Proceed to second-tier testing

Second-Tier Testing for Indeterminate/High FIB-4

When FIB-4 is elevated or indeterminate, you have two evidence-based options 2:

Option 1 (Preferred for FIB-4 near 2.67 or high-risk patients):

  • Proceed directly to liver elastography (vibration-controlled transient elastography/VCTE)
  • Alternative: Enhanced Liver Fibrosis (ELF) test or other direct fibrosis biomarkers

Option 2 (For FIB-4 1.3-2.67 in lower-risk contexts):

  • Implement 1-year lifestyle intervention and cardiometabolic risk factor management
  • Retest FIB-4 after 1 year
  • If still elevated, proceed to elastography

Additional Considerations

Steatosis Detection

While not required for fibrosis assessment, hepatic steatosis can be detected by 3, 4:

  • Ultrasound (first-line imaging for steatosis detection)
  • CT or MRI if ultrasound already performed for other indications
  • MRI-PDFF (most accurate quantification, but not typically first-line)

Complete Metabolic Panel

Consider adding:

  • Albumin (needed for NFS calculation if using that score)
  • Glucose/HbA1c (assess diabetes, a component of NFS)
  • Lipid panel (assess metabolic dysfunction)

Critical Pitfalls to Avoid

Age-related false positives: FIB-4 overestimates fibrosis risk in older patients. Always use the higher threshold (2.0) for those ≥65 years 2, 1.

Missing 10% of advanced fibrosis: FIB-4 has excellent negative predictive value but will miss approximately 10% of individuals with advanced fibrosis 2. Don't rely on a single normal FIB-4 if clinical suspicion remains high.

Low positive predictive value: FIB-4 in the indeterminate range generates many false positives (PPV <70%) 1. This is why second-tier testing with elastography or ELF is essential before making definitive management decisions.

Unselected population screening: These tests perform poorly in unselected general populations. Only use in patients with metabolic risk factors (obesity, type 2 diabetes, metabolic syndrome) or other liver disease risk factors 1.

Emerging Evidence

Recent research suggests MAF-5 (Metabolic dysfunction-associated fibrosis 5) may outperform FIB-4, particularly in younger patients where age-dependent scores show poor sensitivity 5. However, current guidelines still prioritize FIB-4 due to widespread validation and availability 2, 1.

Liver biopsy is not required for clinical management in most MASLD cases 2. Reserve biopsy for clinical trials, ruling out alternative diagnoses (like autoimmune hepatitis), or when non-invasive tests give conflicting results.

Related Questions

Is hepatic steatosis always present in cirrhosis secondary to metabolic‑dysfunction‑associated fatty liver disease?
How should a 29-year-old male with metabolic dysfunction-associated steatotic liver disease (MASLD), hemoglobin A1c 6.3%, dyslipidemia, elevated transaminases (ALT 75 U/L), and liver stiffness of 9.5 kPa be managed?
How is metabolic disease-associated steatosis with moderate (stage 2) fibrosis classified?
Please provide a new draft of a study titled "Disease Progression and Liver‑Related Outcomes in Adults with Metabolic‑Dysfunction‑Associated Steatotic Liver Disease (MASLD): A Retrospective Analysis of Risk Factors and Natural History".
What are the differences between metabolic dysfunction‑associated steatohepatitis (MASH) and non‑alcoholic steatohepatitis (NASH) regarding definition, diagnosis, and management?
In a patient on liothyronine (Cytomel) with suppressed TSH and elevated free T4, should I decrease the liothyronine dose or increase levothyroxine (Synthroid)?
In a patient with methicillin‑resistant Staphylococcus aureus isolated from sputum but no infiltrates on chest radiograph and no clinical signs of pneumonia, should anti‑MRSA antibiotics be administered or is the organism considered colonization?
Is Nasocart (oxymetazoline 0.05% nasal spray) safe and effective for treating nasal congestion, and what are the recommended dosing and contraindications?
What is the recommended octreotide dosing regimen for active upper gastrointestinal bleeding?
A new patient is currently taking insulin glargine (Lantus) 15 units in the morning; can I add a 5‑unit dose in the evening?
What is the recommended treatment for varicella infection during pregnancy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.